NHS

## Health Survey for England 2017 Adult health

## Published 4 December 2018

This report looks at the general health of adults aged 16 and over and the prevalence of chronic pain, diabetes, high cholesterol and hypertension.

## Key findings

- In 2017, 34\% of all adults had chronic pain. This increased with age, ranging from 16\% among adults aged 16 to 24 to $53 \%$ among adults aged 75 and over.
- The proportion of adults with doctor-diagnosed diabetes increased between 1994 and 2017, with some year-on-year fluctuation, from 3\% to 8\% among men and from $2 \%$ to $5 \%$ among women. The increase has been largest for those aged 45 and over.
- In 2017, 20\% of adults with diabetes were undiagnosed (as measured by glycated haemoglobin levels).
- From 1998 to 2017, there has been a decline in the proportion of adults with raised total cholesterol from $67 \%$ to $48 \%$. Throughout the period 1998 to 2017, the prevalence of raised total cholesterol peaked at an older age for women than men.
- The proportion of adults with untreated hypertension declined from 2003 to 2017 for both men ( $20 \%$ to $12 \%$ ) and women ( $16 \%$ to $11 \%$ ).
- In 2017, the detection rate (the proportion of participants with survey-defined hypertension who reported having doctor-diagnosed hypertension), was higher among older than younger age-groups ( $69 \%$ among those aged 75 and over compared with 54\% among those aged 35 to 54).


## Contents

Key findings ..... 1
This is a National Statistics publication ..... 4
Introduction ..... 5
About the survey estimates ..... 5
Main findings ..... 6
General health ..... 7
Introduction ..... 7
General health, longstanding illness and acute sickness, by survey year and sex ..... 7
Chronic pain ..... 9
Introduction ..... 9
Prevalence of chronic pain, by age and sex ..... 10
Prevalence of chronic pain, by quintile of equivalised household income and sex ..... 11
Diabetes ..... 12
Introduction ..... 12
Prevalence of doctor-diagnosed diabetes, by survey year, age and sex ..... 13
Prevalence of total diabetes, including undiagnosed, by survey year, age and sex ..... 14
Cholesterol ..... 15
Introduction ..... 15
Prevalence of raised total cholesterol, by survey year, age and sex 15
Blood pressure ..... 18
Introduction ..... 18
Prevalence of hypertension, by survey year, age and sex ..... 19
Prevalence of hypertension (observed and age-standardised), by region and sex ..... 21
Prevalence of hypertension, by quintile of equivalised household income and sex ..... 21
Systolic blood pressure, by age and sex ..... 21
Detection and treatment of hypertension among participants with survey-defined hypertension, by age and sex ..... 22
Control of hypertension among participants on treatment for hypertension, by age and sex ..... 23
Height and weight ..... 24
Introduction ..... 24
Mean height, by survey year, age and sex ..... 24
Mean weight, by survey year, age and sex ..... 24
Appendix - Technical information ..... 24
Methods ..... 24
Chronic pain ..... 24
Diabetes ..... 25
Technical details ..... 26

## This is a National Statistics publication

National Statistics status means that official statistics meet the highest standards of trustworthiness, quality and public value.

All official statistics should comply with all aspects of the Code of Practice for Official Statistics. They are awarded National Statistics status following an assessment by the Authority's regulatory arm. The Authority considers whether the statistics meet the highest standards of Code compliance, including the value they add to public decisions and debate.

It is NHS Digital's responsibility to maintain compliance with the standards expected of National Statistics. If we become concerned about whether these statistics are still meeting the appropriate standards, we will discuss any concerns with the Authority promptly. National Statistics status can be removed at any point when the highest standards are not maintained, and reinstated when standards are restored.

Find out more about the Code of Practice for Official Statistics at www.statisticsauthority.gov.uk/assessment/code-of-practice

ISBN 978-1-78734-255-2

This report may be of interest to members of the public, policy officials, people working in public health and to commissioners of health and care services to see the general health status of adults in England and the prevalence of various health conditions.

## Introduction

The Health Survey for England is a series of annual surveys designed to measure health and health-related behaviours in adults and children living in private households in England. More information about the survey can be found in the Quick Guide and in more detail in the Methods report at https://digital.nhs.uk/pubs/hse2017.

Each annual survey has covered the adult population aged 16 and over living in private households in England. In 2017, interviews were completed with 7,997 adults.

This report includes a combination of trend tables and HSE 2017 results. It covers general health, chronic pain (2017 only), height and weight, diabetes, cholesterol and hypertension. It provides more detail on hypertension than in the trend tables. Detection and management of high blood pressure, and diabetes are two of several opportunities identified by Public Health England, to prevent and manage cardiovascular disease in the population.

Trend tables on obesity, smoking, alcohol consumption, fruit and vegetable consumption, and physical activity can be found in the HSE 2017 Adult and Child Overweight and Obesity report and the HSE 2017 Adult Behaviours and Risk Factors report. The trend table on cardiovascular disease among adults can be found in the HSE 2017 Cardiovascular Disease report. ${ }^{1}$

## About the survey estimates

The commentary in this report focuses on key trends in the health of adults aged 16 and over since 1993, or the earliest year for which comparable data are available. The Health Survey for England, in common with other surveys, collects information from a sample of the population. The sample is designed to represent the whole population as accurately as possible within practical constraints, such as time and cost. Consequently, statistics based on the survey are estimates, rather than precise figures, and are subject to a margin of error, shown as a $95 \%$ confidence interval. For example the survey estimate might be $24 \%$ with a $95 \%$ confidence interval of $22 \%$ to $26 \%$. A different sample might have given a different estimate, but we expect that the true value of the statistic in the population would be within the range given by the $95 \%$ confidence interval in 95 cases out of 100 .

Where differences are commented on in this report, these reflect the same degree of certainty that these differences are real, and not just within the margins of sampling error. These differences can be described as statistically significant. ${ }^{2}$

Confidence intervals are quoted for key statistics within this report and are also shown in more detail in the Excel tables accompanying this report. Confidence intervals are affected by the size of the sample on which the estimate is based. Generally, the larger the sample, the smaller the confidence interval, and hence the more precise the estimate.

Additional technical information is given in the Appendix to this report.

[^0]
## Main findings

## Self-reported general health

- From 1993 to 1995 the prevalence of very bad or bad general health was steady at $5 \%$. From 1996 to 2017, the prevalence of very bad or bad general health fluctuated between 6\% and 8\%.


## Chronic pain

- In 2017, 34\% of all adults had chronic pain. Prevalence increased with age ranging from $16 \%$ among those aged 16 to 24 to $53 \%$ among those aged 75 and over. More women (38\%) than men (30\%) had chronic pain.
- Chronic pain was more prevalent among lower income groups: in 2017, $43 \%$ of adults in the lowest income quintile had chronic pain compared to $27 \%$ in the highest income quintile.


## Diabetes

- The proportion of adults with doctor-diagnosed diabetes increased between 1994 and 2017, from $3 \%$ to $8 \%$ among men and from $2 \%$ to $5 \%$ among women, with some year-on-year fluctuation. The increase over the period has been largest for those aged 45 and over.
- In 2017, 20\% of adults with diabetes were undiagnosed (as measured by glycated haemoglobin levels).


## High blood cholesterol

- There was a decline in the proportion of adults with raised total cholesterol from 67\% in 1998 to $48 \%$ in 2017.


## High blood pressure

- The prevalence of hypertension among all adults was $31 \%$ in 2003 and remained between $29 \%$ and $30 \%$ between 2005 and 2014. Since 2014 there has been a slight decline to $27 \%$ in 2017. The proportion of adults with untreated hypertension declined over the same period for both men (20\% to 12\%) and women (16\% to 11\%).
- In 2017, high systolic blood pressure increased more steeply with age for women than men. $1 \%$ of women aged 25 to 34 had systolic blood pressure of 140 mmHg or above, rising to $39 \%$ of women aged 75 and over; among men these proportions were $10 \%$ and $31 \%$ respectively.
- Among adults aged 35 and over, $35 \%$ of adults with hypertension were not diagnosed and $41 \%$ were not on treatment.
- In 2017, the detection rate (the proportion of participants with survey-defined hypertension who reported having doctor-diagnosed hypertension), was higher among older than younger age-groups ( $69 \%$ among those aged 75 and over compared with $54 \%$ among those aged 35 to 54).
- In $2017,67 \%$ of adults aged 45 and over on treatment for hypertension had their hypertension controlled (to below $140 / 90 \mathrm{mmHg}$ ). This proportion declined with age from $71 \%$ among those aged 45 to 64 to $60 \%$ among those aged 75 and over.


## Weight

- Between 1993 and 2017, mean weight increased from 78.9 kg to 84.9 kg among men, and from 66.6 kg to 72.8 kg among women.


## General health

## Introduction

Self-assessed general health is an important indicator of the general health of the population. It is a valid measure for predicting future health outcomes and can be used to project use of health services and provide information useful for policy development. In older people, self-assessment of poor overall health has been associated with increased risk of mortality, ${ }^{3}$ and has also been reported to be predictive of functional decline. ${ }^{4}$

Like self-reported general health, longstanding illness is a valuable indicator of the health of the population, and is also an important indicator of inequalities, with strong links between poverty, social class and self-assessed longstanding illness. As the population ages, the number of people with a longstanding illness or condition is expected to rise.

In 2012, the questions on longstanding illness were changed to be consistent with the ONS harmonised disability questions designed for use in social surveys. ${ }^{5}$ The new questions explicitly ask about physical and mental health, separate the concept of disability from illnesses or health conditions, and refer to illnesses or conditions 'lasting or expected to last 12 months or more' rather than 'over a period of time'. ${ }^{6}$

## General health, longstanding illness and acute sickness, by survey year and sex

Between 1993 and 2017, the proportion reporting very good and good general health fluctuated between $74 \%$ and $78 \%$ among men and between $73 \%$ and $76 \%$ among women with no clear pattern of variation. In 2017, the proportions were similar among men ( $77 \%$ ) and women. ( $75 \%$ ). As explained in the Introduction to this report, survey estimates are subject to a margin of error. It is likely that in 2017 the proportion of adults in the population who assessed their general health as very good or good was between $75 \%$ and $78 \%$ of men and between $74 \%$ and $76 \%$ of women.

From 1993 to 1995 the prevalence of very bad or bad general health remained steady at $5 \%$. From 1996 to 2017, the prevalence of very bad or bad general health fluctuated between $6 \%$ and $8 \%$ across the period, and was $7 \%$ in 2017.

In 2017, prevalence of longstanding illness was higher in women (45\%) than men (41\%).

The prevalence of longstanding illness among men increased overall from $40 \%$ in 1993 to around $44 \%$ between 1997 and 2003 but then decreased gradually.

[^1]The current question wording was introduced in 2012. There has been a gradual increase from 35\% in 2012 to $41 \%$ in 2017. As explained in the Introduction to this report, survey estimates are subject to a margin of error. It is likely that in 2017 the proportion of adults in the population with longstanding illness was between $39 \%$ and $43 \%$ of men and between $43 \%$ and $47 \%$ of women.

Among women, prevalence of longstanding illness increased from 40\% in 1993 to $47 \%$ in 2004 but decreased thereafter. Since 2012, the prevalence has increased from $41 \%$ in 2012 to $45 \%$ in 2017.

Figure 1, Table 1

Figure 1: Proportion of adults with at least one longstanding illness, by sex, 1993-2017


Source: NHS Diaital

Acute sickness is defined as any illness or injury (including any longstanding condition) that has caused the participant to cut down in the last two weeks on things they usually did. In 2017, 12\% of men and 17\% of women reported acute sickness. Prevalence has varied between $12 \%$ and $16 \%$ of men and between $14 \%$ and $19 \%$ of women over the period 1993 to 2017. It has been consistently higher in women than in men.

## Chronic pain

## Introduction

Chronic pain refers to pain, an unpleasant sensation associated with actual or potential tissue damage that typically endures for at least three months. ${ }^{7}$ A recent meta-analysis of population studies in the UK, estimated that up to 28 million adults may be affected by chronic pain, between one-third and one-half of the population. ${ }^{8}$ The Health Survey for England 2011 survey found more women than men experience chronic pain ( $31 \%$ of men and $37 \%$ of women), and that prevalence increased with age. ${ }^{9}$

Chronic pain has far-reaching consequences to its sufferers, including a lower quality of life, impacts on mental health, job losses, and can limit daily activities. ${ }^{10,11}$ It is estimated that there are almost five million GP appointments each year due to chronic pain, ${ }^{12}$ with back-pain alone thought to cost the economy around $£ 12.3$ billion per year. ${ }^{10}$ In 2008, for the first time, the Government emphasised the need for better provision for pain management in the Chief Medical Officer's Annual report. ${ }^{10}$ The NHS Five Year Forward view in 2014 set out to support those with long term conditions and manage chronic pain through personalised care plans and support planning. ${ }^{13}$

Chronic pain in the Health Survey for England is defined as pain or discomfort that had troubled the participant all of the time, or on and off, for more than the last three months. This information was provided by participants during the main computerassisted interview. Further details are given in the Appendix to this report.

[^2]
## Prevalence of chronic pain, by age and sex

In 2017, 34\% of all adults had chronic pain, with more women (38\%) than men (30\%) having chronic pain. As explained in the Introduction to this report, survey estimates are subject to a margin of error. It is likely that the proportion of adults in the population who reported having chronic pain was between $29 \%$ and $32 \%$ of men and between $37 \%$ and $40 \%$ of women.

The prevalence of chronic pain increased with age ranging from 16\% among those aged 16 to 24 to $53 \%$ among those aged 75 and over.

Figure 2, Table 2
Figure 2: Prevalence of chronic pain, by age and sex, 2017


The prevalence of chronic pain in 2017 was similar to 2011 when $31 \%$ of men and $37 \%$ of women reported having chronic pain.

## Prevalence of chronic pain, by quintile of equivalised household income and sex

In 2017, the prevalence of chronic pain was higher among those with lower incomes, increasing from $27 \%$ in adults in the highest income quintile to $43 \%$ in the lowest income quintile.

Figure 3, Table 3

Figure 3: Prevalence of chronic pain, by equivalised household income, 2017
Base: Aged 16 and over

- All adults



## Diabetes

## Introduction

Diabetes is characterised by high blood glucose levels (hyperglycaemia). Untreated, hyperglycaemia is associated with damage and possible failure of many organs, especially the eyes, kidneys, nerves, heart, and blood vessels. Diabetes substantially increases the risk of cardiovascular disease (CVD), ${ }^{14}$ and tends to worsen the effect of other risk factors for CVD such as dyslipidaemia (abnormal levels of blood fats), hypertension, smoking and obesity. Being overweight or having a very high waist measurement are risk factors for Type 2 diabetes. ${ }^{15,16}$ Diabetes mellitus (both Types 1 and 2 ) is a leading cause of avoidable mortality; the 2015/16 National Diabetes Audit report, which focused on complications and mortality, estimated that the additional risk of death each year among people with diabetes in England was 32\%, with the highest risk amongst those with Type 1 diabetes. ${ }^{17}$

The Department of Health's National Service Framework for Diabetes, published in 2003, set out a ten-year programme of change to deliver world class care and support for people with diabetes. ${ }^{18}$ This recommended an agreed care plan, a personal diabetes record and named contact within the local service for all people diagnosed with diabetes, or with poor blood glucose control (glycated haemoglobin above 7.5\%). In 2011, the National Institute for Health and Care Excellence (NICE) published quality standards for the care of people with diagnosed diabetes in addition to those set out in the National Service Framework. ${ }^{19}$

HSE measures diabetes in two ways. The prevalence of self-reported doctordiagnosed diabetes is included in the main computer-assisted interview, and these findings are presented in Table 4.

Additionally, glycated haemoglobin ( $\mathrm{HbA}_{1 \mathrm{c}}$ ) levels are measured in blood samples collected at the nurse visit. $\mathrm{HbA}_{1 c}$ reflects average blood sugar levels over the previous two to three months and can therefore be used both to monitor diabetic control in people with diagnosed diabetes, and to detect undiagnosed diabetes. ${ }^{20,21}$

Prevalence of total diabetes, using glycated haemoglobin levels, are presented from 2011 onwards in Table 5, which is limited to participants with a nurse visit and a valid

[^3]$\mathrm{HbA}_{1 c}$ measurement. Total diabetes in the population includes all participants with an $\mathrm{HbA}_{1 \mathrm{c}}$ level of $48 \mathrm{mmol} / \mathrm{mol}$ or above, diagnostic of diabetes, as well as those who reported having diabetes diagnosed by a doctor. Among those with total diabetes, participants with a raised $\mathrm{HbA}_{1 c}$ who did not report having doctor-diagnosed diabetes are defined as having undiagnosed diabetes. ${ }^{22,23}$

Further details are given in the Appendix to this report.
The HSE 2017 Adult and Child Overweight and Obesity report includes information on the associations between overweight, obesity and high waist circumference and the risk of developing diabetes. ${ }^{24}$

## Prevalence of doctor-diagnosed diabetes, by survey year, age and sex

In 2017, $8 \%$ of men and $5 \%$ of women reported doctor-diagnosed diabetes.
Prevalence increased with age and was more common in men than women. As explained in the Introduction to this report, survey estimates are subject to a margin of error. It is likely that the proportion of adults in the population with doctor-diagnosed diabetes was between $7 \%$ and $9 \%$ of men and between $5 \%$ and $6 \%$ of women.

The proportion of adults with doctor-diagnosed diabetes increased between 1994 and 2017, with some year-on-year fluctuation, from $3 \%$ to $8 \%$ among men and from $2 \%$ to 5\% among women.

Figure 4, Table 4
Figure 4: Proportion of adults with doctor-diagnosed diabetes, by sex, 1994-2017
Base: Aged 16 and over


[^4]Increases in doctor-diagnosed diabetes from 1994 to 2017 have been largest for those aged 45 and over. For example, among adults aged 45 to 54, the proportion with doctor-diagnosed diabetes increased more than threefold from 2\% in 1994 to $7 \%$ in 2017. In absolute terms, the rise over this period has been largest among those aged 65 and over.

## Prevalence of total diabetes, including undiagnosed, by survey year, age and sex

Table 5 shows estimates of the level of total diabetes as identified through $\mathrm{HbA}_{1 c}$ levels and self-reported doctor-diagnosed diabetes. It is based on adults who provided a blood sample, and does not include all those who were interviewed. Consequently, the estimates of those with doctor-diagnosed diabetes vary slightly from those in Table 4, which shows the definitive estimates.

In 2017, $7.4 \%$ of adults had diabetes as identified through $\mathrm{HbA}_{1 c}$ levels and doctordiagnosed diabetes. This comprised $5.9 \%$ with doctor-diagnosed diabetes and a further $1.5 \%$ with undiagnosed diabetes.

Levels of total diabetes have varied in the years 2011 to 2017 between $8.6 \%$ and $10.2 \%$ among men, and between $5.6 \%$ and $7.2 \%$ among women. These variations are not statistically significant.

The proportion of adults with undiagnosed diabetes has varied between $1.5 \%$ and $2.4 \%$ since 2011 with no clear pattern, and was $1.5 \%$ in 2017. Similarly, the proportion of those with total diabetes who were undiagnosed has varied since 2011, often being around $30 \%$ and in 2017 it was lower at $20 \%$.

Figure 5, Table 5

Figure 5: Proportion of adults with diagnosed and undiagnosed diabetes, by sex, 2011-2017

Base: Aged 16 and over with a valid glycated haemoglobin measurement


[^5]
## Cholesterol

## Introduction

Cholesterol, also referred to as lipids, is a fatty substance found in the blood, which is needed by the body to function. There are different types of cholesterol including LDL cholesterol (low density lipoprotein), VLDL cholesterol (very low density lipoprotein), and HDL cholesterol. HDL cholesterol is beneficial, as it carries cholesterol away from the arteries back to the liver where it can be excreted. Too much non-HDL cholesterol may be harmful as it can clog blood vessels causing them to become stiff and narrow.

High cholesterol is considered one of the risk factors for cardiovascular diseases, including narrowing of the arteries (atherosclerosis), heart attack, and stroke. Further information on cardiovascular diseases can be found in the HSE 2017 Cardiovascular disease report. ${ }^{25}$

Cholesterol levels were measured via blood samples taken at the nurse visit. Raised total cholesterol is defined as total cholesterol equal to or greater than $5 \mathrm{mmol} / \mathrm{L}$. The prevalence of participants with raised total cholesterol is presented in Table 6 for years 1998, 2003, 2006, 2011, 2014 and 2017. ${ }^{26,27}$

## Prevalence of raised total cholesterol, by survey year, age and sex

In 2017, the prevalence of raised total cholesterol was $48 \%$. Survey estimates are subject to a margin of error, and it is likely that the proportion of adults with raised total cholesterol varies between $46 \%$ and $50 \%$.

From 1998 to 2017 there has been a decline in the proportion with raised total cholesterol from 66\% to 46\% among men, and from 67\% to 50\% among women. Taking into account the margin of error. It is likely that the proportions in the population with raised total cholesterol in 2017 were between $44 \%$ and $49 \%$ of men and between $47 \%$ and $52 \%$ of women. These figures include people taking lipidlowering medication. There has been a large increase in the prescription of statins, ${ }^{28}$ which is probably a major contributing factor to the decline in prevalence of raised total cholesterol.

Figure 6, Table 6

[^6]Figure 6: Proportion of adults with raised total cholesterol, by sex, 1998-2017

Base: Adults aged 16 and over with a valid cholesterol measurement


Throughout the period 1998 to 2017, the prevalence of raised total cholesterol peaked at an older age for women than men. This is likely to reflect three factors. First, rates of premature cardiovascular mortality are higher in men than in women among those with hypercholesterolaemia (high blood cholesterol). ${ }^{29,30}$ Second, risk-based indications for lipid-lowering treatment apply to men at younger ages than in women. ${ }^{31,32}$ Finally, the prescribing of statins to prevent CVD in women lags behind prescribing for men. ${ }^{33}$ In 2017, raised total cholesterol was highest among women aged 55 to 64 (76\%), and among men aged 35 to 54 (63\%).

Figure 7, Table 6

[^7]Figure 7: Prevalence of raised total cholesterol, by age and sex, 2017
Base: Adults aged 16 and over with a valid cholesterol measurement


## Blood pressure

## Introduction

Hypertension (persistent high blood pressure) is an important public health challenge worldwide because of its high prevalence and the associated increase in risk of cardiovascular diseases. It is one of the most important modifiable risk factors for stroke, ischaemic heart disease (such as angina, heart attacks, and heart failure), and renal disease, and one of the most preventable and treatable causes of premature deaths worldwide. ${ }^{34}$

Clinical guidelines for hypertension emphasise the importance of advice on modifiable lifestyle risk factors to reduce the overall risk ${ }^{35}$ of serious cardiovascular events. ${ }^{36}$ The environmental risk factors that have driven the epidemic of CVD include smoking; sedentary lifestyles; diets high in calories, saturated fats, carbohydrate and salt and low fruit and vegetable consumption; and alcohol. ${ }^{37}$ Management of people with hypertension, diabetes, or otherwise at substantial CVD risk includes assessing their risk of CVD and addressing other modifiable risk factors. Lifestyle changes such as reducing alcohol consumption, increasing physical activity, and weight loss if overweight can reduce blood pressure; these changes together with smoking cessation and improved diet can further reduce CVD risk. These may be followed by drug treatment of hypertension, hypercholesterolaemia (high blood cholesterol), and/or hyperglycaemia (high blood sugar levels), as appropriate.

It has been estimated that more than 9,000 heart attacks and at least 14,000 strokes could be prevented over the next three years by improved diagnosis and management of high blood pressure, high cholesterol, and atrial fibrillation. ${ }^{38,39}$ These calculations assumed 5 million undiagnosed cases each of hypertension and diabetes in England and $40 \%$ of cases that were poorly controlled (hypertension) or did not receive all eight care processes (diabetes).

High blood pressure is defined for this report as a systolic blood pressure (SBP) at or above 140 mmHg or diastolic blood pressure (DBP) at or above 90 mmHg or on medication prescribed for high blood pressure, as described in the 2003 report ${ }^{40}$

[^8](referred to as 'survey-defined hypertension'). ${ }^{41}$ Participants are classified into one of four groups as follows:

- Normotensive untreated: SBP below 140 mmHg and DBP below 90 mmHg , not currently taking medication for blood pressure.
- Hypertensive controlled: SBP below 140 mmHg and DBP below 90 mmHg , currently taking medication for blood pressure.
- Hypertensive uncontrolled: SBP at or greater than 140 mmHg and/or DBP at or greater than 90 mmHg , currently taking medication for blood pressure.
- Hypertensive untreated: SBP at or greater than 140 mmHg and/or DBP at or greater than 90 mmHg , not currently taking medication for blood pressure.


## Prevalence of hypertension, by survey year, age and sex

Trend data on the prevalence of hypertension are presented from 2003 and 2005 onwards in Table 7, ${ }^{42}$ using measurements taken with the Omron HEM207 sphygmomanometer to measure blood pressure. ${ }^{43}$ The prevalence of hypertension among all adults was $31 \%$ in 2003 and remained between $29 \%$ and $30 \%$ between 2005 and 2014. Since 2014 there has been a slight decline to $27 \%$ in 2017.

The prevalence of hypertension has fallen since 2014 from $32 \%$ to $28 \%$ among men but has remained relatively stable among women (from $27 \%$ to $25 \%$ across the period).

The proportion of adults with untreated hypertension decreased from 2003 to 2017 for both men ( $20 \%$ to $12 \%$ ) and women ( $16 \%$ to $11 \%$ ).

Figure 8, Table 7

[^9]Figure 8: Total and untreated hypertension by sex, 20032017
Base: Aged 16 and over with valid blood pressure measurements


Source: NHS Digital

In 2017, more men (28\%) than women (25\%) had hypertension• As explained in the Introduction to this report, survey estimates are subject to a margin of error. It is likely that the proportion of men in the population with hypertension was between $26 \%$ and $31 \%$, and the proportion of women was between $23 \%$ and $27 \%$. As Figure 9 shows, the patterns for the increases in hypertension prevalence with age were different in men and women.

Figure 9, Table 7

Figure 9: Prevalence of hypertension, by age and sex, 2017
Base: Adults aged 16 and over with valid blood pressure measurements


Prevalence of hypertension (observed and age-standardised), by region and sex

There was no statistically significant variation in the prevalence of hypertension by region after age-standardisation.

Table 8

## Prevalence of hypertension, by quintile of equivalised household income and sex

The prevalence of hypertension in 2017 was $24 \%$ in the highest income quintile and $28 \%$ in the lowest income quintile but these differences in the prevalence of hypertension are not statistically significant.

Table 9

## Systolic blood pressure, by age and sex

In 2017, 15\% of all adults had high blood pressure defined as systolic blood pressure of 140 mmHg or above. This prevalence is lower than in Table 7, which looks at all hypertension (27\%), including people taking medication for hypertension who have their hypertension controlled. Table 7 is limited to people with valid blood pressure measurements and data on medication, whereas Table 10 includes adults for whom medication data were not available. Consequently, Tables 7 and 10 are not directly comparable:

In addition, $17 \%$ of all adults had a systolic blood pressure reading of 130 mmHg to less than 140 mmHg . This was more common in men ( $22 \%$ ) than women ( $13 \%$ ). In younger age groups the proportion of women with this level was very low, being $4 \%$ or less of those aged under 35.

High systolic blood pressure increased more steeply with age for women than men. $1 \%$ of women aged 25 to 34 had systolic blood pressure of 140 mmHg or above, rising
to $39 \%$ of women aged 75 and over; among men these proportions were $10 \%$ and $31 \%$ respectively.

Figure 10, Table 10
Figure 10: Systolic blood pressure, by age and sex
Base: Aged 16 and over with valid blood pressure measurements


Source: NHS Digital

## Detection and treatment of hypertension among participants with survey-defined hypertension, by age and sex

Among adults aged 35 and over, the proportion of those with survey-defined hypertension who reported doctor-diagnosed hypertension (the detection rate), and the proportion on treatment are presented in Table 11. This table is limited to adults aged 35 and over due to the small numbers with hypertension among adults aged under 35 .

In 2017, $65 \%$ of adults aged 35 and over with survey-defined hypertension had their hypertension detected (the proportion who reported having doctor-diagnosed hypertension). The detection rate was higher among older than younger age groups (69\% among those aged 75 and over compared with 54\% among those aged 35 to 54).

The treatment rate is the proportion with survey-defined hypertension who were on treatment to reduce blood pressure and was $59 \%$ among adults aged 35 and over. It increased with age among all adults, from $38 \%$ among those aged 35 to 54 to $75 \%$ among those aged 75 and over.

Figure 11, Table 11

Figure 11: Detection and treatment of hypertension among participants with survey-defined hypertension, by age, 2017

Base: Aged 35 and over with survey-defined hypertension


Source: NHS Digital

## Control of hypertension among participants on treatment for hypertension, by age and sex

Table 12 shows the proportion of adults aged 45 and over on treatment for hypertension whose hypertension was controlled to less than $140 / 90 \mathrm{mmHg}$. This table is limited to adults aged 45 and over due to the small numbers on treatment for hypertension among adults aged under 45.

In 2017, 67\% of adults aged 45 and over on treatment for hypertension had their hypertension controlled (to below $140 / 90 \mathrm{mmHg}$ ). This proportion declined with age from $71 \%$ among those aged 45 to 64 to $60 \%$ among those aged 75 and over.

Table 12

## Height and weight

## Introduction

This report presents trends in mean height and mean weight by age and sex from 1993 onwards. Surveillance of height and weight was one of the original purposes of the Health Survey for England series. Their use to monitor obesity, by calculating body mass index (BMI) is reported in the HSE 2017 Adult and Child Overweight and Obesity report. ${ }^{44}$

## Mean height, by survey year, age and sex

In 2017 the mean height of men was 175.3 cm , and of women was 161.9 cm . Between 1993 and 2017, mean height varied little from year to year.

## Mean weight, by survey year, age and sex

Between 1993 and 2017, mean weight increased from 78.9 kg to 84.9 kg among men, and from 66.6 kg to 72.8 kg among women.

Among men, mean weight increased least among those aged 16 to 24 (an increase of 1.6 kg , from 73.1 kg to 74.7 kg between 1993 and 2017), and most among those aged 45 to 54 (an increase of 7.9 kg , from 81.5 kg to 89.4 kg between 1993 and 2017).

Among women, mean weight increased least among those aged 55 to 64 (an increase of 4.1 kg , from 69.7 kg to 73.8 kg between 1993 and 2017), and most among those aged 25 to 34 (an increase of 8.2 kg , from 65.5 kg to 73.7 kg ).

Table 16

## Appendix - Technical information

## Methods

Further details of the protocols for collecting measurements and blood samples can be found in the HSE 2017 Methods report. Full questionnaires are included in the survey Documentation. Both of these are available via https://digital.nhs.uk/pubs/hse2017.

## Chronic pain

All adult participants were asked in their interview if they were currently troubled by pain and discomfort either all of the time or on and off. If participants reported that they were, they were asked whether they had had the pain or discomfort for more than three months. Those who said yes to this question were classified as having 'chronic pain'.

Participants suffering from chronic pain were asked additional questions about their pain or discomfort, including:

- which areas of the body the pain was in;
- the intensity of their pain;

[^10]- how much their pain interfered with aspects of their life; and
- support or help they had received.

Further data on chronic pain sufferers can be found in the HSE2017 dataset.

## Diabetes

HSE measures diabetes in two ways. The prevalence of self-reported doctordiagnosed diabetes was included in the main computer-assisted interview in 1994, 1998, 2003, 2006, and each year from 2009 onwards, and these findings are presented in Table 4.

The HSE interview makes no distinction between Type 1 and Type 2 diabetes. In earlier years (up to HSE 2003) it was assumed that participants who reported having doctor-diagnosed diabetes before the age of 35 and who were having insulin therapy at the time of the survey had Type 1 diabetes, and all other participants with doctordiagnosed diabetes were classified as having Type 2 diabetes. However, small but increasing numbers of people are now being diagnosed with Type 2 diabetes below the age of $35,45,46,47,48$ and some adults with Type 2 diabetes are now prescribed insulin therapy, ${ }^{49,50}$ so these distinctions are no longer reliable.

In addition to the interview question, glycated haemoglobin $\left(\mathrm{HbA}_{1 c}\right)$ levels are measured in blood samples collected at the nurse visit. HbA1c reflects average blood sugar levels over the previous two to three months and can therefore be used both to monitor diabetic control in people with diagnosed diabetes, and to detect undiagnosed diabetes. ${ }^{51,52}$

Prevalence of total diabetes is limited to participants with a nurse visit and a valid $\mathrm{HbA}_{1 c}$ measurement. Total diabetes in the population includes all participants with an $\mathrm{HbA}_{1 \mathrm{c}}$ level of $48 \mathrm{mmol} / \mathrm{mol}$ or above, diagnostic of diabetes, as well as those who reported having diabetes diagnosed by a doctor. Among those with total diabetes,

[^11]participants with a raised $\mathrm{HbA}_{1 c}$ who did not report having doctor-diagnosed diabetes are defined as having undiagnosed diabetes. ${ }^{53,54}$

## Technical details

Trend tables present the results within the general population sample, although in some years boost sample data have been included. For example, some estimates for 2002 are based on data from young adults in both boost and general population samples to increase the precision of the results. For 2005, the boost sample of older people is included in the estimates for people aged 65 and over. In these years, boost sample cases have been excluded from the estimates for all men, all women and all adults. ${ }^{55}$

Since 2013, standard errors (shown in some tables) have been calculated for all survey years using a complex samples module of the statistical package. In 2014, standard errors for adult estimates in years up to 2002 were also recalculated using the complex samples module. This complex samples module takes account of the complex survey design and weighting used in the HSE rather than assuming a simple random sample. ${ }^{56}$ In the earlier trend tables, standard errors for years up to 2002 did not use a complex samples module, and therefore indicated narrower margins of error than those shown in the tables from 2013 onwards.

In 2003, non-response weighting was introduced for the first time in the HSE series. Since the weighted data provide more accurate information for the individual years for which they are available, the analysis of trends in this report focuses on the weighted estimates for 2003 onwards. ${ }^{57}$

The impact of the weighting can be seen in the 2006 adults' trend tables, available at https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/health-survey-for-england-2006-latest-trends. These present unweighted estimates (directly comparable with previous years) and weighted estimates for 2003 to 2006 .

[^12]
# Information and technology for better health and care 

www.digital.nhs.uk

03003035678
enquiries@nhsdigital.nhs.uk
© @nhsdigital

ISBN 978-1-78734-255-2
This publication may be requested in large print or other formats.

Published by NHS Digital, part of the Government Statistical Service

Copyright © 2018 NHS Digital.
NHS Digital is the trading name of The Health and Social Care Information Centre a non-departmental body created by statute.

## OGL

You may re-use this document/publication (not including logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0.

To view this licence visit
www.nationalarchives.gov.uk/doc/open-government-licence or write to the Information Policy Team, The National Archives, Kew, Richmond, Surrey, TW9 4DU; or email: psi@nationalarchives.gsi.gov.uk


[^0]:    ${ }^{1}$ These and other reports from the Health Survey for England 2017 are available via the report website https://digital.nhs.uk/pubs/hse2017
    ${ }^{2}$ Statistical significance does not imply substantive importance; differences that are statistically significant are not necessarily meaningful or relevant.

[^1]:    ${ }^{3}$ Mossey JM, Shapiro E. Self-rated health: a predictor of mortality among the elderly. American Journal of Public Health 1982;72:800-808.
    ${ }^{4}$ Idler EL, Kasl SV. Self-ratings of health: do they also predict change in functional ability? Journal of Gerontology: Social Sciences. 1995;50B:S344-S353.
    ${ }^{5}$ This was recommended by the Disability, Health and Carers Primary Standards in 2011. See Office for National Statistics. Harmonised Concepts and Questions for Social Data Sources: Primary
    Standards. Long-lasting Health Conditions and IIInesses; Impairments and Disability. ONS, Newport, 2015.
    ${ }^{6}$ Further details about the change to the longstanding illness questions are provided in the 2012 report, Volume 2, Chapter 3, Section 3.4 and in Appendix D to Volume 2.
    http://content.digital.nhs.uk/catalogue/PUB13218

[^2]:    ${ }^{7}$ Merskey H, Bogduk N (eds). Classification of Chronic Pain. International Association for the Study of Pain, Seattle, 1994. Part III, Pain Terminology, updated in 2011. www.iasppain.org/Content/NaviationMenu/Publications/Freebooks/default/htm
    8 Fayaz A, Croft P, Langford RM et al. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open 2016;6:e010364.
    ${ }^{9}$ Bridges S. Chronic pain. Chapter 9 in Craig R, Mindell J (eds). Health Survey for England 2011. Health and Social Care information Centre, Leeds, 2012.
    ${ }^{10}$ Donaldson L. Pain: Breaking through the barrier. Chapter in 150 years of the Annual Report of the Chief Medical Officer: On the state of public health 2008. DH, London, 2009.
    www.dh.gov.uk/en/Publicationsandstatistics/Publications/AnnualReports/DH 096206
    ${ }^{11}$ Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: Prevalence, impact on daily life and treatment. European Journal of Pain 2006;10:287-333.
    ${ }^{12}$ Elliott AM, Smith BH, Penny KI, et al. The epidemiology of chronic pain in the community. Lancet 1999;354:1248-1252.
    ${ }^{13}$ Care and Support Planning Working Group and Coalition for Collaborative Care. Personalised care and support planning handbook: The journey to person-centred care. NHS England, London 2015. https://www.england.nhs.uk/wp-content/uploads/2016/04/core-info-care-support-planning-1.pdf

[^3]:    ${ }^{14}$ Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in the Framingham population. Sixteen year follow-up. Diabetes 1974;23:105-111.
    ${ }^{15}$ Diabetes UK. Preventing Type 2 diabetes. https://www.diabetes.org.uk/Preventing-Type-2-diabetes/
    ${ }^{16}$ Klein S, Allison DB, Heymsfield SB et al. Waist circumference and cardiometabolic risk: a consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. American Journal of Clinical Nutrition. 2007;85:5:1197-1202.
    ${ }^{17}$ National Diabetes Audit 2015-16. Report 2a: complications and mortality. NHS Digital 2017. https://digital.nhs.uk/catalogue/PUB30030
    ${ }^{18}$ Department of Health. National Service Framework for Diabetes: Delivery Strategy. DH, London, 2002. www.yearofcare.co.uk/sites/default/files/images/national\%20service\%20\%20delivery\%20strategy.pdf
    ${ }^{19}$ National Institute for Health and Care Excellence. NICE Quality Standard Programme: Diabetes in adults. NICE, London, 2011. www.nice.org.uk/guidance/qs6
    ${ }^{20}$ World Health Organisation. Use of Glycated Haemoglobin $\left(\mathrm{HbA}_{1 c}\right)$ in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. www.who.int/diabetes/publications/diagnosis diabetes2011/en
    ${ }^{21}$ Moody A, Cowley G, Ng Fat L, et al. Social inequalities in prevalence of diagnosed and undiagnosed diabetes and impaired glucose regulation in participants in the Health Surveys for England series. BMJ Open. 2016;6:e010155. doi:10.1136/bmjopen-2015-010155

[^4]:    ${ }^{22}$ In Table 7, values of $\mathrm{HbA}_{1 c}$ were adjusted in 2013, 2014, 2015, 2016 and 2017 to make them comparable to years before HSE 2013, due to changes in calibrators. The calibrator used after $19^{\text {th }}$ September 2013 produced lower glycated haemoglobin results compared with the previous one.
    ${ }^{23}$ Full details of the HSE blood sample analytical methods and equipment can be found in the HSE 2017 Methods report at https://digital.nhs.uk/pubs/hse2017
    ${ }^{24}$ These and other reports from the Health Survey for England 2017 are available via the report website https://digital.nhs.uk/pubs/hse2017

[^5]:    Source: NHS Dipital

[^6]:    ${ }^{25}$ This and other reports from the Health Survey for England 2017 are available via the report website https://digital.nhs.uk/pubs/hse2017
    ${ }^{26}$ Values from 2011 and 2014 have been adjusted to make the measurements comparable to measurements made before HSE 2010, where there was a change in calibrators.
    ${ }^{27}$ Full details of the HSE blood sample protocols, analytical methods and equipment can be found in the HSE 2017 Methods report at https://digital.nhs.uk/pubs/hse2017
    ${ }^{28}$ Keefe A, Nazareth I, Peterson I. Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care data. Clinical Epidemiology. 2016;8:123-132.

[^7]:    ${ }^{29}$ Mikkola T, Gissler M, Merikukka M et al. Sex Differences in Age-Related Cardiovascular Mortality. PLoS One 2013;8:e63347
    ${ }^{30}$ Bhatnagar P, Wickramasinghe K, Wilkins E, et al. Trends in Epidemiology of cardiovascular disease in the UK. Heart. 2016;102:1945-1952.
    ${ }^{31}$ National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification. 2014;
    https://www.nice.org.uk/guidance/cg181/resources/cardiovascular-disease-risk-assessment-and-reduction-including-lipid-modification-pdf-35109807660997
    ${ }^{32}$ National Institute for Health and Care Excellence (NICE), CVD risk assessment and management. 2014; https://cks.nice.org.uk/cvd-risk-assessment-and-management\#!scenario
    ${ }^{33}$ Mindell J, Aresu M, Zaninotto P et al. Improving lipid profiles and increasing use of lipid-lowering therapy in England: results from a national cross-sectional survey-2006. Clinical Endocrinology. 2011;86:621-627.

[^8]:    ${ }^{34}$ World Health Organization. Global Health Observatory (GHO) Data, Raised blood pressure: Situation and Trends. 2016; http://www.who.int/gho/ncd/risk factors/blood pressure prevalence text/en/
    ${ }^{35}$ Giuseppe M, De Backer G, Doniniczak A et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension. 2007;25:6:1105-1187.
    ${ }^{36}$ National Institute for Health and Care Excellence (NICE). Clinical management of primary hypertension in adults. NICE Clinical Guideline 127. NICE, London, 2011 (updated 2016). https://www.nice.org.uk/guidance/cg127
    ${ }^{37}$ National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE Clinical Guideline 181. NICE, London, 2014 (updated 2016). https://www.nice.org.uk/guidance/cg181
    ${ }^{52}$ Public Health England (PHE). Action plan for cardiovascular disease (CVD) prevention: England. London: PHE, England, 2017. (page 15)
    https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment data/file/6481 90/cardiovascular disease prevention action plan 2017 to 2018.pdf
    ${ }^{53}$ NHS England. NHS launches new drive to save thousands of people from heart attacks and strokes. 2017 https://www.england.nhs.uk/2017/09/nhs-launches-new-drive-to-save-thousands-of-people-from-heart-attacks-and-strokes
    ${ }^{40}$ Sproston K, Primatesta P (eds). Health Survey for England 2003. Volume 3: Methodology and documentation. The Stationery Office, London, 2004.

[^9]:    ${ }^{41}$ The HSE cannot be completely accurate in identifying people with hypertension as the definition requires persistently raised blood pressure; HSE measures the blood pressure three times but on a single occasion.

[^10]:    ${ }^{44}$ This and other reports from the Health Survey for England 2017 are available via the report website https://digital.nhs.uk/pubs/hse2017

[^11]:    ${ }^{45}$ Ehtisham S, Barrett TG, Shaw NJ. Type 2 diabetes mellitus in UK children-an emerging problem. Diabetic Medicine, 2000;17:867-71.
    ${ }^{46}$ Drake A, Smith A, Betts P et al. Type 2 diabetes in obese white children. Archives of Disease in Childhood, 2002;86:207-8.
    ${ }^{47}$ Diabetes UK. Facts and stats. London, 2016. https://diabetes-resources-production.s3-eu-west-1.amazonaws.com/diabetes-storage/migration/pdf/DiabetesUK Facts Stats Oct16.pdf
    ${ }^{48}$ Wilmot E, Idris I. Early onset type 2 diabetes: risk factors, clinical impact and management. Therapeutic Advances in Chronic Disease. 2014;5:234-244.
    ${ }^{49}$ Barnett A, Begg A, Dyson P et al. Insulin for type 2 diabetes: choosing a second-line insulin regimen. International Journal of Clinical Practice 2008;62:1647-53.
    ${ }^{50}$ Rubino A, McQuay LJ, Gough SJ et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. Diabetic Medicine 2007;24:1412-8.
    ${ }^{51}$ World Health Organisation. Use of Glycated Haemoglobin $\left(H b A_{1 c}\right)$ in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. www.who.int/diabetes/publications/diagnosis diabetes2011/en
    ${ }^{52}$ Moody A, Cowley G, Ng Fat L, et al. Social inequalities in prevalence of diagnosed and undiagnosed diabetes and impaired glucose regulation in participants in the Health Surveys for England series. BMJ Open. 2016;6:e010155. doi:10.1136/bmjopen-2015-010155

[^12]:    ${ }^{53}$ In Table 7, values of $\mathrm{HbA}_{1 c}$ were adjusted in 2013, 2014, 2015, 2016 and 2017 to make them comparable to years before HSE 2013, due to changes in calibrators. The calibrator used after $19^{\text {th }}$ September 2013 produced lower glycated haemoglobin results compared with the previous one.
    ${ }^{54}$ Full details of the HSE blood sample analytical methods and equipment can be found in the HSE 2017 Methods report at https://digital.nhs.uk/pubs/hse2017
    ${ }^{55}$ Data from older people in care homes collected for the 2000 survey are not included in trend tables as there are likely to be significant differences in the health of older people living in private households and in care homes.
    ${ }^{56}$ Full details of the HSE sample can be found in the HSE 2017 Methods report available via https://digital.nhs.uk/pubs/hse2017
    ${ }^{57}$ In 2003, key survey variables using weighted and unweighted estimates were compared. This comparison showed that there are small differences between weighted and unweighted results, which are generally larger for men than women. See Blake, M. Weighting the data. Section 7.4.2, in Sproston K, Primatesta P (eds). Health Survey for England 2003. Volume 3: Methodology and documentation. The Stationery Office, London, 2004.

